On September 5, 2019 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, reported its participation in the following industry conferences in September (Press release, Unum Therapeutics, SEP 5, 2019, View Source [SID1234539309]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell & Gene Therapy Bioprocessing & Commercialization, September 9 – 12, Boston, MA.

Geoffrey Hodge, Chief Technical Officer at Unum Therapeutics, will present "Designing the Cell Therapy Facility of the Future by Learning from the Past" on Tuesday, September 10, 2019 at 8:40 a.m. ET.
CAR-TCR Summit, September 10 – 13, Boston, MA.

David O’Donnell, Director, Technology Operations at Unum Therapeutics, will present "Managing Leukapheresis for Autologous Cell Therapies" on Tuesday, September 10, 2019 at 9:00 a.m. ET.

Ann Ranger, Ph.D., Senior Director, Translational Medicine and Biomarkers at Unum Therapeutics, will present "Clinical Pharmacology of a Unique Antibody Coupled T Cell (ACTR) Therapy Combination Product" on Thursday, September 12, 2019 at 1:00 p.m. ET.
2nd International Conference on Lymphocyte Engineering (ICLE), September 13 – 15, London, UK.

Seth Ettenberg, Ph.D., Chief Scientific Officer at Unum Therapeutics, will present "Addressing the Challenges of T Cell Therapies in Solid Tumors" on Friday, September 13, 2019 at 6:50 p.m. BST / 1:50 p.m. EDT in London, United Kingdom.